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Liver Resection" To Drain or not to Drain?
ABSTRACT
Fong, Y., Brennan, M. F., Brown, K., Heffernan, N.,
Blumgart, L. H, (1996) Drainage is unnecessary after
elective liver resection, The American Journal of Surgery,
171, 158-162.
Purpose: A prospective, randomized trial was per-
formed to determine if intra-abdominal drainage
catheters are necessary after elective liver resection.
Patients and Methods: Between April 1992 and April
1994, 120 patients subjected to liver resection,
stratified by extent of resection and by surgeon,
were randomized to receive or not receive operative
closed-suction drainage. Operative blood loss was
not an exclusion criteria, and no patient who
consented to the study was excluded.
Results: Eighty-seven patients (73%) had resection of
one hepatic lobe or more (27 lobectomies, 54
trisegmentectomies, and 6 bilobar atypical resec-
tions) and 33 had less than a lobectomy (8 wedge
resections or enucleations, 9 segmentectomies, and
16 bisegmentectomies). Eighty-four patients (70%)
had metastatic cancer and 36 patients (30%) had
primary liver pathology. There were no differences
in outcome, including length of hospital stay (no
drain, 13.4 4- 0.9 days; drain, 13.1 4- 0.8 days; P not
significant [NS]), mortality (no drain, 3.3%; drain,
3.3%), complication rate (no drain, 43%; drain, 48%;
P NS), or requirement for subsequent percuta-
neous drainage (no drain, 18%; drain, 8%; P NS).
All infected collections (n 3) occured in operatively
drained patients. Two other complications were
directly related to the operatively placed drains.
One patient developed a subcutaneous abscess at
the drain site, and a second developed a subcuta-
neous drain tract tumor recurrence as the only
current site of recurrence.
Conclusion: In the first 50 consecutive resections
performed since the conclusion of this trial, only 4
patients (8%) have required subsequent percuta-
neous drainage. We conclude that abdominal drai-
nage is unnecessary after elective liver resection,Am
J Surg., 1996, 171, 158-162.
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PAPER DISCUSSION
This paper concerns 120 patients undergoing liver
resection, including 87 undergoing lobectomy or
more. Patients were randomized intraopera-
tively which is in itself not an optimal design
and details of all excluded patients are not
included.
Patients were randomly allocated to closed
suction drains (Jackson-Pratt) or controls. No
significant difference in death (3.3%), hospital
stay (13 days), biliary fistula (5%). Five opera-
tively drained patients required peritoneal drai-
nage whereas 11 in the undraine,d group (18%)
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required percutaneous drainage none of them
were infected whereas 3 of the drain group
collections were infected.
The paper concludes that drainage after liver
resection is unnecessary. I have several problems
with this:
1. The power of this study to detect adverse
outcome in theno drain group is very limited
with approximately 50 patients in each group,
if a complication which occured with a rate of
5% in the drained group was three times more
frequent in the undrained group this would not
be detected.
2. The study does not show any advantage to not
draining. In fact, there was significantly higher
need for percutaneous post-op drainage.
3. Whilst two complications of drainage were
seen drain site abscess and drain site cancer
recurrence, ie. the former would seem a
relatively minor complication and even if the
drain site appeared to be the only site of
recurrence in the second patient, it would seem
likely that if enough viable tumour cells were
transplanted into the drain site that theywould
have developed at other sites in time.
David L. Morris
Professor of Surgery
Department of Surgery
The St George Hospital
Sydney NSW 2217 Australia
Is Chemoembolisation of Value
in Inoperable Primary Hepatocellular Carcinoma
ABSTRACT
Ryder, S. D., Rizzi, P. M., Metivier, E., Karani, J. and
Williams, R. (1996) Chemoembolisation with lipiodol and
doxorubicin: applicability in British patients with hepato-
cellular carcinoma, Gut, 38, 125-128.
Chemoembolisation has been extensively used as
primary treatment for unresectable hepatocellular
carcinoma (HCC). In this unit, 185 patients with a
new diagnosis of HCC not amenable to surgery were
seen between 1988 and 1991. Intended therapy for
these patients was chemoembolisation with doxo-
rubicin (60 mg/m2) and lipiodol, repeated at six week
intervals until it was technically no longer possible
o.r until complete tumour response had been
obtained. Chemoembolisation was possible in 67 of
the 185 (37%). Reasons for exclusion were portal vein
occlusion (n 36), decompensated cirrhosis (n 44),
distant metastases (n 5), diffuse tumour or unsui-
table anatomy (tumour or vasculature) (n=11),
patient refusal (n=11), and other (n=11). Patients
excluded from treatment survived for a median of 10
weeks (range 3 days-19 months). In patients treated,
18 had small HCC (4cm) and 49 had large or
multifocal HCC. Chemoembolisation was carried
out a median of two sessions for small and three
sessions for large tumours. Ten of 18 patients with
small HCC showed a 50% or greater reduction in
tumour size. Five of 49 patients with large or
multifocal tumours showed a response to treatment.
Median overall survival for treated patients was
36 weeks (range 3 days-4 years). One patient has
subsequently undergone liver transplantation with
no recurrence and minimal residual disease at
transplantation. Two other patients are alive three
years after chemoembolisation, one with no evidence
of recurrent disease. No patient was thought suitable
for surgery after their response to chemoembolisa-
tion. Chemotherapy related complications were seen
in 22%. Complications were significantly more
common in patients with larger tumours and poor
liver reserve. Five patients died as a result of chemo-
therapy related complications. In conclusion, only
one third of UK patients with unresectable HCC are
treatable by chemoembolisation. Results with small